We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions.
Xenon is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.Read More
Xenon Provides Key Regulatory Updates on XEN007 and XEN1101
January 28, 2019
Xenon Pharmaceuticals Outlines 2019 Key Milestones
January 6, 2019
Xenon to Present at the Stifel 2018 Healthcare Conference
November 7, 2018